The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression.

Gene ontology analysis of the 230 significant genes affected by AS602801-treatment demonstrated that there was a highly significant enrichment of genes associated with the cell cycle that were altered (FDR = 8.5e-8), even after correcting for the fact that there were only 770 genes on the panel and they were all associated with cancer related pathways.

also in 132,142 other papers

IHC staining for AR protein levels in xenografts demonstrated some downregulation of AR expression in AS602801 treated cells, but the variability in these data did not reach statistical significance (Supplementary Figure S5).

also in 111,027 other papers